A detailed history of Brown Brothers Harriman & CO transactions in Genmab A/S stock. As of the latest transaction made, Brown Brothers Harriman & CO holds 228 shares of GMAB stock, worth $4,694. This represents 0.0% of its overall portfolio holdings.

Number of Shares
228
Previous 175 30.29%
Holding current value
$4,694
Previous $4,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$23.84 - $28.48 $1,263 - $1,509
53 Added 30.29%
228 $5,000
Q1 2021

May 13, 2021

SELL
$30.92 - $44.4 $19,696 - $28,282
-637 Reduced 78.45%
175 $6,000
Q4 2020

Feb 16, 2021

BUY
$33.66 - $40.76 $7,775 - $9,415
231 Added 39.76%
812 $33,000
Q3 2020

Nov 16, 2020

SELL
$33.07 - $38.68 $3,836 - $4,486
-116 Reduced 16.64%
581 $21,000
Q2 2020

Aug 13, 2020

BUY
$20.05 - $33.89 $13,974 - $23,621
697 New
697 $24,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Brown Brothers Harriman & CO Portfolio

Follow Brown Brothers Harriman & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

News

Stay updated on Brown Brothers Harriman & CO with notifications on news.